Small Cell Lung Cancer
Conditions
Brief summary
\[Study Design\] This study is a single arm, multi-center phase II study of vistusertib monotherapy in patients with relapsed small cell lung cancer (SCLC) harboring RICTOR amplification. Patients will receive vistusertib monotherapy (50 mg BID per os every 12 hours) until they demonstrate objective disease progression or they meet any other discontinuation criteria. \[Primary Objective\] To investigate the efficacy of vistusertib monotherapy in patients with relapsed SCLC patients harboring RICTOR amplification as 2nd or 3rd line therapy
Interventions
DRUGvistusertib (AZD2014)
vistusertib(AZD2014): 50 mg BID per os every 12 hours administration daily. One cycle is consisted of 3 weeks.
Sponsors
AstraZeneca
Samsung Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Vistusertib monotherapy (50 mg BID per os every 12 hours)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\[Inclusion Criteria\] * Provision of informed consent prior to any study specific procedures * Men and women aged at least 18 years * Small cell lung cancer harboring RICTOR amplification * Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 with no deterioration over the previous 2 weeks * Minimum life expectancy of 12 weeks * Patients must have acceptable bone marrow, liver and renal function measured within 14 days prior to administration of study treatment as defined below: * At least one measurable lesion that can be accurately assessed by imaging or physical examination at baseline and follow up visits. * No history of non-autologous bone marrow transplant.
Exclusion criteria
* Participation in another clinical study with an investigational product during the last 21 days. * Prior chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents within 21 days of starting study treatment. Prior use of an investigational monoclonal antibody therapy within 3 months. * Major surgery within 4 weeks prior to study entry (excluding placement of vascular access), or minor surgery (excluding tumour biopsies) within 14 days of first dose of study treatment. * Exposure to strong or moderate inhibitors or inducers of CYP3A4/5, Pgp (MDR1) and BCRP if taken within the stated washout periods before the first dose of study treatment (see Appendix 1) * Exposure to specific substrates of the drug transporters OATP1B1, OATP1B3, MATE1 and MATE2K within the appropriate wash-out period * Any haemopoietic growth factors within 14 days prior to receiving study treatment. * Pre-treatment with other PI3K, AKT, dual PI3K/mTRO and mTOR inhibitors * Spinal cord compression and/or brain metastases unless asymptomatic or treated and stable off steroids for at least 4 weeks prior to start of study treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective reponse rate (ORR) by RECIST 1.1 | Up to 20 months | Assessments to be performed using CT or MRI scans. To be measured according to RECIST 1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Adverse Events as Assessed by CTCAE v4.03 | Up to 20 months | CTCAE v4.03 |
| Duration of response | Up to 20 months | Assessments to be performed using CT or MRI scans. To be measured according to RECIST 1.1 |
| Disease control rate | at 12 weeks | Assessments to be performed using CT or MRI scans. To be measured according to RECIST 1.1 |
| Overall survival (OS) | Up to 20 months | Kaplan-Meier method |
| Progression-free survival (PFS) | Up to 20 months | Kaplan-Meier method |
Countries
South Korea
Outcome results
None listed